VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease
Completed
Conditions studied: COVID-19 Disease
In brief
To assess blood levels of vasoactive mediators that may regulate pulmonary endothelial permeability and contribute to multi-organ injury in patients with COVID-19 disease and to correlate the levels of these mediators with disease outcomes such as ICU admission, length of ventilatory support, respiratory failure, kidney failure, heart failure, and death.
Key facts
- Study ID
- NCT04587323
- Run by
- University of Alabama at Birmingham
- People needed
- 75
- Starts
- 2020-05-22
- Expected to finish
- 2025-10-06
- Last updated by the study team
- 2026-02-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Positive test for COVID-19 (SARS-CoV-2 infection)
- >=18 years
- Blood (plasma) specimen(s) available in the CCTS biorepository
You may not qualify if…
- <18 years
- Lack of blood specimen
Where it is running
- University of Alabama at Birmingham — Birmingham, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.